In addition to reducing body mass index, treatment with the GLP-1 receptor agonist liraglutide lowered serum testosterone levels in overweight and obese PCOS patients (Niafar et al. 2016), and has also been found to increase SHBG and improve menstrual regularity (Nylander et al. 2017). Here, GLP1R is linked to polycystic ovary syndrome.